However, it should be noted that, in our study, Neu REFIX is an adjunct disease modifying treatment has resulted in a dystrophin expression nearly 70% higher than that observed in mdx-vehicle or mdx-control mice, providing proof of concept for its potential as an adjunct therapy in DMD. This evidence concerns the gene DMD and Duchenne muscular dystrophy.